Time to catch up on breaking stem cell news

As the first and only market research firm to track the stem cell industry, BioInformant has released new coverage of stem cell industry news. Check it out and let me know what you think?

Pluristem Announces Promising Results from Non-Human Primate (NHP) Pilot Study of PLX-R18 in Acute Radiation Syndrome

Pluristem Therapeutics Inc. (NASDAQ: PSTI), (TASE: PSTI), a leading developer of placenta-based cell therapy products, released promising results from its non-human primates (NHP) pilot study for PLX-R18 as a treatment for Acute Radiation Syndrome (ARS). The study was designed to assess the safety and efficacy of PLX-P18 following intramuscular injection into irradiated and non-irradiated NHPs. Efficacy measures included survival as well as level of bone marrow function, which is affected by exposure to high levels of radiation as may occur in a nuclear accident or attack.

Interview with Dr. Denver Lough, President and CEO of PolarityTE

Recently, I had the honor of interviewing Dr. Denver Lough, Chairman, President, CEO, and CSO of PolarityTE. PolarityTE is an innovative company that has developed a platform to regenerate a variety of functionally polarized tissue substrates, such as skin, bone, muscle, cartilage, blood vessels, peripheral nerves, and more. In this exclusive interview, we explore the origins of PolarityTE as a company. We also explore the company’s novel technology, five-year vision, and future directions.

Breakthrough Regenerative Therapeutics Company Establishes Scientific Advisory Board

Fortuna Fix Inc., (“Fortuna”), a private, clinical-stage biotech company is aiming to be the first to eliminate the need for embryonic and fetal stem cells by using direct reprogramming of autologous cells to treat neurodegenerative diseases. Fortuna has announced the launch of its Scientific Advisory Board (“SAB”) with Professor Michael Fehlings, MD, PhD, Father Kevin FitzGerald, S.J., PhD, COL (R) Dallas Hack, MD, MPH, and Professor James Giordano, PhD. Fortuna’s two flagship technologies – autologous directly reprogrammed neural precursor cells (“drNPC”) and regeneration matrix (“RMx?”) – are poised to lead a revolution in neuro-regeneration.

Cynata Files for New Patent for Oncology Applications

Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), has filed a further patent application with IP Australia covering certain novel and innovative applications of its proprietary Cymerus? mesenchymal stem cell (MSC) technology. The new patent application, should it mature to a granted patent, will provide additional protection for the Company’s unique MSC technology, particularly in fields related to cancer treatment.

Future of Regenerative Medicine Congress with Kyle Cetrulo, CEO of AuxoCell Laboratories

In this interview with Kyle Cetrulo, CEO of AuxoCell Laboratories, we discuss the upcoming 3rd Annual Perinatal Stem Cell Congress, as well as future directions for regenerative medicine at large. Perinatal stem cells are stem cells derived from afterbirth (perinatal) tissues, such as the amnion, chorion, placenta (including both placental blood cells and tissue), umbilical cord blood (UCB) and umbilical cord tissue (Wharton’s Jelly). Called "The Future of Regenerative Medicine Congress: Extending and Improving Life with Perinatal, Adipose and Bone Marrow Stem Cells," the meeting will take place on May 19-21 in Teaneck, NJ. 

Governments on Alert and Stockpiling Antidotes: Dangers of Acute Radiation Syndrome from Nuclear Accidents and Attacks

Many governments, including the U.S. and Japan, are well aware of the dangers to their populations of exposure to high levels of radiation from nuclear accidents or dirty bomb attacks. Whereas Japan’s population was recently exposed at Fukushima following the tsunami of 2011, the U.S. DoD has been stockpiling acute radiation syndrome (ARS) countermeasures as a precaution for many years. During a military parade on April 15th, North Korea displayed weapons including an intercontinental ballistic missile (ICBM) that could be capable of reaching the U.S. ARS may have just become a larger threat to health than it was a few weeks ago.

Be Great,

Cade 

President/CEO of BioInformant.com

"1st and Only Market Research Firm to Specialize in the Stem Cell Industry"